Naga Alpha N Acetylgalactosaminidase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@kanzaki1989]
<table> [@chabas1991]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Alpha-N-Acetylgalactosaminidase</th></tr> [@mayatepek1999]
<tr><td><strong>Gene Symbol</strong></td><td>NAGA</td></tr> [@umapathysivam2001]
<tr><td><strong>Full Name</strong></td><td>Alpha-N-Acetylgalactosaminidase</td></tr> [@bakker1997]
<tr><td><strong>Chromosome</strong></td><td>22q13.2</td></tr> [@herskovits2020]
<tr><td><strong>NCBI Gene ID</strong></td><td>[4668](https://www.ncbi.nlm.nih.gov/gene/4668)</td></tr> [@naga]
<tr><td><strong>OMIM</strong></td><td>[104170](https://www.omim.org/entry/104170)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000163580</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P17050](https://www.uniprot.org/uniprot/P17050)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Schindler Disease, Kanzaki Disease, Alpha-N-Acetylgalactosaminidase Deficiency</td></tr>
</table>
</div>
Naga Alpha N Acetylgalactosaminidase is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-gene"> [@kanzaki1989]
<table> [@chabas1991]
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Alpha-N-Acetylgalactosaminidase</th></tr> [@mayatepek1999]
<tr><td><strong>Gene Symbol</strong></td><td>NAGA</td></tr> [@umapathysivam2001]
<tr><td><strong>Full Name</strong></td><td>Alpha-N-Acetylgalactosaminidase</td></tr> [@bakker1997]
<tr><td><strong>Chromosome</strong></td><td>22q13.2</td></tr> [@herskovits2020]
<tr><td><strong>NCBI Gene ID</strong></td><td>[4668](https://www.ncbi.nlm.nih.gov/gene/4668)</td></tr> [@naga]
<tr><td><strong>OMIM</strong></td><td>[104170](https://www.omim.org/entry/104170)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000163580</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P17050](https://www.uniprot.org/uniprot/P17050)</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Schindler Disease, Kanzaki Disease, Alpha-N-Acetylgalactosaminidase Deficiency</td></tr>
</table>
</div>
NAGA (Alpha-N-Acetylgalactosaminidase) is a lysosomal hydrolase that catalyzes the removal of alpha-N-acetylgalactosamine (GalNAc) residues from glycoconjugates. The gene is located on chromosome 22q13.2 and encodes a protein of approximately 46 kDa. NAGA belongs to the glycoside hydrolase family 27 and plays an essential role in lysosomal catabolism of glycoproteins and glycolipids.
NAGA deficiency causes two distinct clinical syndromes: Schindler disease (infantile/childhood onset) and Kanzaki disease (adult onset). Both are classified as [lysosomal storage disorders](/diseases/lysosomal-storage-disorders) characterized by the accumulation of glycoproteins with terminal alpha-GalNAc residues.
The NAGA gene spans approximately 12.5 kb on chromosome 22 and contains 9 exons. Multiple alternatively spliced transcripts have been described, though the functional significance of these variants remains under investigation.
NAGA exhibits broad tissue expression:
NAGA is primarily localized to:
The NAGA protein contains key structural elements:
NAGA catalyzes the hydrolysis of:
NAGA hydrolyzes:
NAGA participates in the stepwise degradation of glycoproteins:
NAGA works in concert with:
Schindler disease (MIM 609241) is caused by complete or near-complete NAGA deficiency:
| Feature | Type I (Infantile) | Type II (Childhood) |
|---------|-------------------|---------------------|
| Onset | 4-12 months | 1-3 years |
| Neurodevelopment | Severe regression | Progressive delay |
| Seizures | Intractable | Common |
| Vision | Optic atrophy | Progressive loss |
| Survival | Usually fatal | Variable |
Pathogenesis:
Kanzaki disease (MIM 609750) is caused by partial NAGA deficiency:
| Feature | Description |
|---------|-------------|
| Onset | Adulthood (20-40 years) |
| Skin | Angiokeratoma corporis diffusum |
| Nervous system | Peripheral neuropathy, mild cognitive decline |
| Other | Fatigue, joint pain |
Pathogenesis:
Variant forms with intermediate presentations:
Current and emerging therapies:
| Approach | Status | Notes |
|----------|--------|-------|
| Enzyme replacement | Research | Challenges with CNS delivery |
| Gene therapy | Preclinical | AAV vectors under development |
| Substrate reduction | Research | Migalastat analog approaches |
| Symptomatic treatment | Standard of care | Seizure control, supportive care |
NAGA deficiency illustrates broader themes in neurodegeneration:
Studies on NAGA deficiency inform understanding of:
Insights from NAGA research inform:
Naga knockout mice show:
Transgenic expression of human NAGA:
Current research focuses on:
The study of Naga Alpha N Acetylgalactosaminidase has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.